S. Larsson's Profile

Role	Title	Level	Year	L/R
🐜	Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis 80 auth. Alessandro Cassini, L. Högberg, D. Plachouras, A. Quattrocchi, Ana Hoxha, G. S. Simonsen, M. Colomb-Cotinat, M. Kretzschmar, B. Devleesschauwer, M. Cecchini, D. A. Ouakrim, T. C. Oliveira, M. Struelens, C. Suetens, D. Monnet, ... R. Strauss, K. Mertens, T. Struyf, B. Catry, K. Latour, I. Ivanov, E. Dobreva, A. Tambić Andrašević, S. Šoprek, A. Budimir, N. Paphitou, H. Žemličková, Stefan Schytte Olsen, Ute Wolff Sönksen, Pille Märtin, M. Ivanova, O. Lyytikäinen, J. Jalava, B. Coignard, T. Eckmanns, Muna Abu Sin, S. Haller, G. Daikos, A. Gikas, S. Tsiodras, F. Kontopidou, Á. Tóth, Á. Hajdú, Ólafur Guólaugsson, K. Kristinsson, S. Murchan, K. Burns, P. Pezzotti, C. Gagliotti, U. Dumpis, Agne Liuimiene, M. Perrin, M. Borg, S. D. de Greeff, J. Monen, M. Koek, P. Elstrøm, D. Żabicka, A. Deptuła, W. Hryniewicz, M. Caniça, P. Nogueira, Paulo André Fernandes, Vera Manageiro, G. Popescu, R. Șerban, Eva Schréterová, S. Litvová, M. Štefkovičová, J. Kolman, I. Klavs, A. Korošec, B. Aracil, Á. Asensio, M. Pérez-Vázquez, H. Billström, S. Larsson, J. Reilly, Alan P. Johnson, S. Hopkins	10	2019	10 🐜
🐜	Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. 10 auth. E. Wolff, E. Wolff, K. Elfström, H. H. Cange, S. Larsson, S. Larsson, ... H. Englund, P. Sparén, A. Roth, A. Roth	5	2018	5 🐜
🐜	Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. 10 auth. E. Wolff, E. Wolff, K. Elfström, H. H. Cange, S. Larsson, S. Larsson, ... H. Englund, P. Sparén, A. Roth, A. Roth	5	2018	5 🐜
🐬	Willingness to Pay for Health Improvements Using Stated Preferences: Prevention Versus Treatment. E. Wolff, S. Larsson, M. Svensson	3	2020	3 🐬
🐜	Cost-effectiveness of pneumococcal vaccination for elderly in Sweden. 7 auth. E. Wolff, J. Storsaeter, Å. Örtqvist, P. Nauclér, S. Larsson, T. Lepp, ... A. Roth	3	2020	3 🐜
🦁	A microsimulation model projecting the health care costs for resistance to antibacterial drugs in Sweden 7 auth. S. Larsson, M. Prioux, T. Fasth, A. Ternhag, J. Struwe, U. Dohnhammar, ... L. Brouwers	3	2018	3 🦁
🦁	Production loss and sick leave caused by antibiotic resistance: a register-based cohort study S. Larsson, M. Svensson, A. Ternhag	3	2022	3 🦁
🐬	Quality-adjusted life years among people who inject drugs in a needle syringe program in Sweden M. Kåberg, S. Larsson, Jakob Bergström, A. Hammarberg	1	2022	1 🐬
🐬	Cost-effectiveness of influenza vaccination of elderly in SwedenEllen Wolff E. Wolff, S. Larsson, Adam Roth, S. Bastami	0	2016	0 🐬
🦁	Cost-Effectiveness Analysis of Temocillin Treatment in Patients with Febrile UTI Accounting for the Emergence of Antibiotic Resistance S. Larsson, C. Edlund, P. Nauclér, M. Svensson, A. Ternhag	0	2022	0 🦁
🐬	Future costs of antibiotic resistance Jakob Bergström, C. Bergman, U. Dohnhammar, T. Fasth, S. Larsson, J. Struwe	0	2018	0 🐬